AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Perspectives
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.
Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations
By Autumn Jeong, MD
CAR-T cell therapy is the established standard second-line treatment for primary refractory or early relapsed diffuse large B-cell lymphoma, supported by mature, practice-defining trial data.
Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations
By Autumn Jeong, MD
CAR-T cell therapy is the established standard second-line treatment for primary refractory or early relapsed diffuse large B-cell lymphoma, supported by mature, practice-defining trial data.
Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations
By Autumn Jeong, MD
CAR-T cell therapy is the established standard second-line treatment for primary refractory or early relapsed diffuse large B-cell lymphoma, supported by mature, practice-defining trial data.
Milk Thistle and Cancer: Why the Warning Label Exists
By The Cancer News Team
The milk thistle cancer warning is usually a California Prop 65 disclosure about trace heavy metals, not proof of harm. Learn the separate estrogen concern for hormone-sensitive cancers and treatment interactions.
Milk Thistle and Cancer: Why the Warning Label Exists
By The Cancer News Team
The milk thistle cancer warning is usually a California Prop 65 disclosure about trace heavy metals, not proof of harm. Learn the separate estrogen concern for hormone-sensitive cancers and treatment interactions.
Milk Thistle and Cancer: Why the Warning Label Exists
By The Cancer News Team
The milk thistle cancer warning is usually a California Prop 65 disclosure about trace heavy metals, not proof of harm. Learn the separate estrogen concern for hormone-sensitive cancers and treatment interactions.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
The Post–CAR-T Playbook: What Comes Next?
By Bhagirathbhai Dholaria, MD
CAR-T cures fewer than half of patients with relapsed large B-cell lymphoma, and outcomes after CAR-T failure depend heavily on when relapse occurs
The Post–CAR-T Playbook: What Comes Next?
By Bhagirathbhai Dholaria, MD
CAR-T cures fewer than half of patients with relapsed large B-cell lymphoma, and outcomes after CAR-T failure depend heavily on when relapse occurs
The Post–CAR-T Playbook: What Comes Next?
By Bhagirathbhai Dholaria, MD
CAR-T cures fewer than half of patients with relapsed large B-cell lymphoma, and outcomes after CAR-T failure depend heavily on when relapse occurs
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
The Silent Ecosystem Within Clinical Trials
By Zoë Swainson, MHA
Clinical trial outcomes do not emerge solely by science. They also emerge from an invisible ecosystem of trust, coordination, compassion and operational excellence.
The Silent Ecosystem Within Clinical Trials
By Zoë Swainson, MHA
Clinical trial outcomes do not emerge solely by science. They also emerge from an invisible ecosystem of trust, coordination, compassion and operational excellence.
The Silent Ecosystem Within Clinical Trials
By Zoë Swainson, MHA
Clinical trial outcomes do not emerge solely by science. They also emerge from an invisible ecosystem of trust, coordination, compassion and operational excellence.
Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop
By Abdullah Mohammad Khan, MBBS
Indefinite lenalidomide maintenance after transplant has been standard practice in multiple myeloma for years, largely on the strength of older trials that never directly tested whether stopping was safe.
Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop
By Abdullah Mohammad Khan, MBBS
Indefinite lenalidomide maintenance after transplant has been standard practice in multiple myeloma for years, largely on the strength of older trials that never directly tested whether stopping was safe.
Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop
By Abdullah Mohammad Khan, MBBS
Indefinite lenalidomide maintenance after transplant has been standard practice in multiple myeloma for years, largely on the strength of older trials that never directly tested whether stopping was safe.